Clinical Trial

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-09.
Trial Details
NCT Number NCT07535099
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Health Services Research
Enrollment 104 participants
Start Date 2026-03-13
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-18